Amgen Inc.

163.32 +0.60(0.37%) Date:

Amgen Inc.

Earnings Whisper: Amgen, Inc. (NASDAQ:AMGN), Xilinx, Inc. (NASDAQ:XLNX)

Smart Stock News has outlined March quarter earnings whisper for both companies before the earnings announcements in after-market hours today

Amgen, Inc. (NASDAQ:AMGN): Repatha Uptake Will Increase Gradually

Given that 11M US patients have not reached optimal LDL and significant risk reduction, Amgen believes Repatha is on its way to become one of the largest selling products

Amgen, Inc.'s (NASDAQ:AMGN) Q1'17 Earnings Preview

Baird updated its model to reflect changes in US scripts, pricing, and potential impact of inventory on US sales

Jefferies Downgraded Amgen, Inc. (NASDAQ:AMGN) to Hold and Reset PT at $180

Repatha (new class of hypercholesterolemia drug, PCSK9 inhibitor) is viewed as a key product for AMGN with significant commercial potential (~13%/8% of the firm's prior/current PT)

Amgen Inc. (AMGN) What Is The Company Worth If Repatha Was Bigger Than Its Base Case Assumption

The firm thinks that the Grey Sky could take longer (maybe 2018) to fully appreciate whether growth is picking up for Amgen after outcomes data